X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Australia begins production of Oxford Covid-19 vaccine, plans to manufacture 30 million doses

Content Team by Content Team
16th November 2020
in Manufacturing, News
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A Covid-19 vaccine co-developed by pharmaceutical company AstraZeneca and the University of Oxford is seen as one of the most promising of all the experimental candidates currently being tested on humans. Dubbed ‘Covishield‘, the vaccine is currently in the phase-III or the last stage of clinical trial and the results are expected to be published in December. Meanwhile, Australia has already begun local production of the Oxford Covid-19 vaccine, with roughly 30 million doses planned to be manufactured.

As reported by IANS, Australian biotech firm CSL has signed a deal with AstraZeneca to begin pre-emptive production of the vaccine, for release during the first half of 2021 should remaining tests prove successful. Also Read – COVID-19 Live Updates: Cases in India surge to 85,53,657 while death toll reaches 1,26,611

“We are undertaking these manufacturing activities at-risk and in parallel with the clinical trials and approvals processes in recognition of the significant urgency of the Covid-19 pandemic,” the news agency quoted CSL’s Chief Scientific Officer Andrew Nash as saying. Also Read – Pfizer-BioNTech vaccine found 90% effective in preventing Covid-19

While the production has started, the vaccine will not be released for use anytime soon. Australia’s government regulatory authority, the Therapeutic Goods Administration (TGA), will review the development process before approving the shots for general use.

When it’s available, a person may need a two-dose regime. This means the planned 30 million doses would be used to vaccinate 15 million people.

Previous Post

CCRM and McMaster Innovation Park (MIP) Partner to Buildand Operate Biomanufacturing Campus

Next Post

CPhI & P-MEC China 2020 adapts to customer needs with hybrid pharma event

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products

CPhI & P-MEC China 2020 adapts to customer needs with hybrid pharma event

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In